Absci Corp
NASDAQ:ABSI

Watchlist Manager
Absci Corp Logo
Absci Corp
NASDAQ:ABSI
Watchlist
Price: 2.56 USD 0.39% Market Closed
Market Cap: 290.7m USD
Have any thoughts about
Absci Corp?
Write Note

Absci Corp
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Absci Corp
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Absci Corp
NASDAQ:ABSI
Long-Term Debt
$4.7m
CAGR 3-Years
-12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Long-Term Debt
$31.2B
CAGR 3-Years
13%
CAGR 5-Years
14%
CAGR 10-Years
11%
Danaher Corp
NYSE:DHR
Long-Term Debt
$16.3B
CAGR 3-Years
-12%
CAGR 5-Years
0%
CAGR 10-Years
19%
Mettler-Toledo International Inc
NYSE:MTD
Long-Term Debt
$1.9B
CAGR 3-Years
5%
CAGR 5-Years
11%
CAGR 10-Years
18%
Agilent Technologies Inc
NYSE:A
Long-Term Debt
$2.1B
CAGR 3-Years
-8%
CAGR 5-Years
11%
CAGR 10-Years
0%
IQVIA Holdings Inc
NYSE:IQV
Long-Term Debt
$12.3B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
20%
No Stocks Found

Absci Corp
Glance View

Market Cap
292.3m USD
Industry
Life Sciences Tools & Services

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 216 full-time employees. The company went IPO on 2021-07-22. The firm has developed an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. The company uses synthetic biology technologies and deep learning artificial intelligence (AI) to predict, identify, design, construct, screen, select and scale production of biologic drug candidates, and learn from the data it generates. The firm has drug candidates in approximately nine active programs, eight of the active programs are focused on developing production cell lines for drug candidates that the Company's partners are developing. The company has one discovery program, focused on lead optimization with Astellas. The Company’s active programs include Bispecific monoclonal antibodies (mAb), Bispecific T-cell engager, Cytokine, Fab, Multivalent Fc-fusion, Plasma protein and mAb.

ABSI Intrinsic Value
1.45 USD
Overvaluation 43%
Intrinsic Value
Price

See Also

What is Absci Corp's Long-Term Debt?
Long-Term Debt
4.7m USD

Based on the financial report for Dec 31, 2023, Absci Corp's Long-Term Debt amounts to 4.7m USD.

What is Absci Corp's Long-Term Debt growth rate?
Long-Term Debt CAGR 3Y
-12%

Over the last year, the Long-Term Debt growth was -46%. The average annual Long-Term Debt growth rates for Absci Corp have been -12% over the past three years .

Back to Top